Alaric J. Dyckman
Bristol-Myers Squibb (Belgium)(BE)
Publications by Year
Research Areas
Sphingolipid Metabolism and Signaling, Cytokine Signaling Pathways and Interactions, Protein Kinase Regulation and GTPase Signaling, Melanoma and MAPK Pathways, Catalytic Alkyne Reactions
Most-Cited Works
- → The First Intermolecular Transition Metal-Catalyzed [5+2] Cycloadditions with Simple, Unactivated, Vinylcyclopropanes(2000)161 cited
- → Transition Metal-Catalyzed [5+2] Cycloadditions with Substituted Cyclopropanes: First Studies of Regio- and Stereoselectivity(1999)93 cited
- → A New and Practical Five-Carbon Component for Metal-Catalyzed [5 + 2] Cycloadditions: Preparative Scale Syntheses of Substituted Cycloheptenones(2000)83 cited
- → Design, Synthesis, and Anti-inflammatory Properties of Orally Active 4-(Phenylamino)-pyrrolo[2,1-f][1,2,4]triazine p38α Mitogen-Activated Protein Kinase Inhibitors(2007)81 cited
- → N-Amination of Pyrrole and Indole Heterocycles with Monochloramine (NH2Cl)(2004)79 cited
- → Transition Metal-Catalyzed [5 + 2] Cycloadditions of 2-Substituted-1-vinylcyclopropanes: Catalyst Control and Reversal of Regioselectivity(1999)77 cited
- → Modulators of Sphingosine-1-phosphate Pathway Biology: Recent Advances of Sphingosine-1-phosphate Receptor 1 (S1P1) Agonists and Future Perspectives(2017)60 cited
- → Discovery of 4-(5-(Cyclopropylcarbamoyl)-2-methylphenylamino)-5-methyl-N-propylpyrrolo[1,2-f][1,2,4]triazine-6-carboxamide (BMS-582949), a Clinical p38α MAP Kinase Inhibitor for the Treatment of Inflammatory Diseases(2010)57 cited
- → The Discovery of Orally Active Triaminotriazine Aniline Amides as Inhibitors of p38 MAP Kinase(2004)50 cited
- → Purine derivatives as potent Bruton’s tyrosine kinase (BTK) inhibitors for autoimmune diseases(2014)39 cited